Company profilePharmaceutical#255 of 1,318 in Pakistan✓ No DRAP alerts

FASSGEN PHARMACEUTICALS

Pharmaceutical company · 71 brands · 59 molecules

Ranked #85 of 137 companies in Anti-Infectives

71 registered products 28 pharmaceutical brands 59 distinct molecules 0 DRAP alerts

Company overview

71
registered products
28
pharmaceutical brands
59
distinct molecules
2
therapeutic classes
0
DRAP alerts

FASSGEN PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 71 product registrations across 59 distinct molecules. Its portfolio is concentrated in Anti-Infectives and Antiemetics & Antinauseants. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by FASSGEN

2 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Anti-Infectives 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

1
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20251

Top molecules by brand count

Omeprazole4 brands
Diclofenac4 brands
Artemether2 brands
Lumefantrine2 brands
Mecobalamin2 brands
Esomeprazole2 brands
Escitalopram2 brands
Azithromycin2 brands

Therapeutic classes

Anti-Infectives · 1Antiemetics & Antinauseants · 1

Conditions treated

General Infections · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official1 products · Rs 417.17 – Rs 417.17
Servaid1 products · Rs 475 – Rs 475
Median across source: Rs 475

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

SHROOQ PHARMACEUTICALS32 shared molecules
NEUTRO PHARMA (PVT) LTD.32 shared molecules
BIO LABS (PVT) LTD.28 shared molecules
CARAWAY PHARMACEUTICALS27 shared molecules
PANACEA PHARMACEUTICALS25 shared molecules
GOODMAN INTERNATIONAL,25 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SHROOQ PHARMACEUTICALS holds 21 molecules not in this portfolio
AcitretinAcyclovirAcyclovir Inf/OralCefiximeDiclofenacDiclofenac Potassium
NEUTRO PHARMA (PVT) LTD. holds 125 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAmikacinAnastrazoleAnastrozole
Wilshire Laboratories (Private) Limited holds 131 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin

Get the full profile for FASSGEN

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.